Pharmacokinetics of the major metabolites of D-penicillamine in patients with rheumatoid arthritis.

Abstract

The pharmacokinetic disposition of D-penicillamine and its major metabolites, penicillamine cysteine disulfide ( PSSC ) and penicillamine disulfide ( PSSP ) has been studied in eight patients with rheumatoid arthritis. Plasma concentrations of D-penicillamine, PSSP and PSSC displayed similar characteristics in terms of times to maximum concentrations and biphasic elimination from plasma. Initial t1/2 (alpha) phase ranged from 0.86 to 4.41 h for parent drug and 0.81 to 4.41 h for metabolites. Final t1/2 (beta phase) ranged from 3.4 to 9.45 h for D-penicillamine and 5.62 to 21.7 h for the metabolites. Total drug and metabolites detected in urine accounted for 12.0 to 48.7% of oral drug.

• Authors: G Carruthers, M Harth, D Freeman, D Weir, R Rothwell, M Butler
• Journal: Clinical and investigative medicine. Medecine clinique et experimentale (Clin Invest Med) Vol. 7 Issue 1 Pg. 35-40 ( 1984) ISSN: 0147-958X [Print] Canada
• PMID: 6723122 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• penicillamine disulfide
• penicillamine cysteine disulfide
• Penicillamine
• Cysteine

Topics

• Adult
• Aged
• Arthritis, Rheumatoid (blood, drug therapy)
• Biotransformation
• Chromatography, High Pressure Liquid
• Cysteine (analogs & derivatives, blood)
• Dose-Response Relationship, Drug
• Female
• Humans
• Metabolic Clearance Rate
• Middle Aged
• Penicillamine (analogs & derivatives, blood, therapeutic use)